Freitag B, Fehring L, Uncovska M, Olsacher A, Meister S
Health Econ Rev. 2024; 14(1):81.
PMID: 39365482
PMC: 11451222.
DOI: 10.1186/s13561-024-00558-8.
Moye-Holz D, Vogler S
Appl Health Econ Health Policy. 2021; 20(1):67-77.
PMID: 34228312
PMC: 8752537.
DOI: 10.1007/s40258-021-00670-4.
Ho J
Popul Dev Rev. 2019; 45(1):7-40.
PMID: 31123371
PMC: 6527318.
DOI: 10.1111/padr.12228.
Danzon P
Pharmacoeconomics. 2018; 36(12):1395-1405.
PMID: 30062518
DOI: 10.1007/s40273-018-0696-4.
Wouters O, Kanavos P, Mckee M
Milbank Q. 2017; 95(3):554-601.
PMID: 28895227
PMC: 5594322.
DOI: 10.1111/1468-0009.12279.
Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
Moye-Holz D, van Dijk J, Reijneveld S, Hogerzeil H
Global Health. 2017; 13(1):53.
PMID: 28764738
PMC: 5540413.
DOI: 10.1186/s12992-017-0281-1.
A comparison of generic drug prices in seven European countries: a methodological analysis.
Wouters O, Kanavos P
BMC Health Serv Res. 2017; 17(1):242.
PMID: 28359273
PMC: 5374620.
DOI: 10.1186/s12913-017-2184-5.
A price comparison of recently launched proprietary pharmaceuticals in the UK and the US.
Jorgensen J, Kefalas P
J Mark Access Health Policy. 2016; 4.
PMID: 27695606
PMC: 5023951.
DOI: 10.3402/jmahp.v4.32754.
Is cost-related non-collection of prescriptions associated with a reduction in health? Findings from a large-scale longitudinal study of New Zealand adults.
Jatrana S, Richardson K, Norris P, Crampton P
BMJ Open. 2015; 5(11):e007781.
PMID: 26553826
PMC: 4654342.
DOI: 10.1136/bmjopen-2015-007781.
Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?.
Srivastava D, McGuire A
BMC Public Health. 2014; 14:767.
PMID: 25073407
PMC: 4287477.
DOI: 10.1186/1471-2458-14-767.
Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S, Nguyen N
Medicare Medicaid Res Rev. 2014; 4(1).
PMID: 24918023
PMC: 4049516.
DOI: 10.5600/mmrr.004.01.a01.
Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs.
Brekke K, Dalen D, Holmas T
Eur J Health Econ. 2013; 15(9):937-51.
PMID: 24146261
DOI: 10.1007/s10198-013-0536-6.
Impact of parallel trade on pharmaceutical firm's profits: rise or fall?.
Guo S, Hu B, Zhong H
Eur J Health Econ. 2012; 14(2):345-55.
PMID: 22286662
DOI: 10.1007/s10198-012-0380-0.
Ontario's plunging price-caps on generics: deeper dives may drown some drugs.
Anis A, Harvard S, Marra C
Open Med. 2011; 5(3):e149-52.
PMID: 22046229
PMC: 3205826.
The (paper) work of medicine: understanding international medical costs.
Cutler D, Ly D
J Econ Perspect. 2011; 25(2):3-25.
PMID: 21595323
PMC: 4511963.
DOI: 10.1257/jep.25.2.3.
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Blankart C, Stargardt T, Schreyogg J
Pharmacoeconomics. 2010; 29(1):63-82.
PMID: 21073206
DOI: 10.2165/11539190-000000000-00000.
Why U.S. health care expenditure and ranking on health care indicators are so different from Canada's.
Spithoven A
Int J Health Care Finance Econ. 2008; 9(1):1-24.
PMID: 18592374
DOI: 10.1007/s10754-008-9044-0.
Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
Kyle M, Allsbrook J, Schulman K
Health Serv Res. 2008; 43(4):1308-24.
PMID: 18355258
PMC: 2517281.
DOI: 10.1111/j.1475-6773.2008.00838.x.
The influence of market exclusivity on drug availability and medical innovations.
Glover G
AAPS J. 2007; 9(3):E312-6.
PMID: 17915833
PMC: 2751479.
DOI: 10.1208/aapsj0903034.
End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).
Dor A, Pauly M, Eichleay M, Held P
Int J Health Care Finance Econ. 2007; 7(2-3):73-111.
PMID: 17653860
DOI: 10.1007/s10754-007-9024-9.